News

Company News & Events

ORYZON Closes € 10.5 Million (12.1 M USD) Debt Financing

4 May 2016

BARCELONA, SPAIN and CAMBRIDGE MA.

• With these funds the company completes its Global Funding of € 27 Million (31.1 Million USD)

Oryzon Genomics (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, has announced that it has closed a Debt Funding round of 10.5 Million Euros (12.1 Million USD), completing this way a Global Funding since July 2015 of 27 Million Euros (31.1 Million USD).

Click here to see the full Press Release

Posted In: 
News
Investors

Share this story